title: Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs.
abstract: Recombinant canine granulocyte colony-stimulating factor (rcG-CSF) was administered to clinically normal dogs, cyclic-hematopoietic dogs, and dogs undergoing autologous bone marrow transplantation, to determine whether rcG-CSF could be used to stimulate WBC production and function in normal and neutropenic dogs. To the normal dogs, rcG-CSF was administered by SC injection at rates of 1 microgram/kg of body weight, q 12 h; 2 micrograms/kg, q 12 h; or 5 micrograms/kg, q 12 h. A significant dose-dependent increase in the WBC count resulted from the stimulation of bone marrow progenitor cells. The increased WBC count was characterized by mature neutrophilia and monocytosis. Neutrophil myeloperoxidase and phagocytic activity were normal in rcG-CSF-treated normal dogs, demonstrating the production of normal functional neutrophils in response to rcG-CSF treatment. Recombinant canine G-CSF prevented neutropenia and associated clinical signs but did not completely eliminate the cycling of neutrophils in cyclic-hematopoietic dogs when it was administered at rates of 1 microgram/kg, q 12 h, and 2.5 micrograms/kg, q 12 h. The time to bone marrow reconstitution was not decreased in dogs treated with rcG-CSF at a rate of 2.5 micrograms/kg, q 12 h, for 13 days following autologous bone marrow transplantation. On the basis of our findings, we suggest that treatment with rcG-CSF is an effective way to stimulate myelopoiesis in dogs, but that the dose of rcG-CSF required to stimulate WBC production will vary depending on the cause of neutropenia. Recombinant canine G-CSF should be useful in stimulating production and maintaining function of WBC for treatment of clinical diseases seen commonly in veterinary practice.
authors.affiliation: Department of Environmental Practice, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071.
authors.forename: L
authors.initials: L
authors.lastname: Mishu
authors.forename: G
authors.initials: G
authors.lastname: Callahan
authors.forename: Z
authors.initials: Z
authors.lastname: Allebban
authors.forename: J M
authors.initials: JM
authors.lastname: Maddux
authors.forename: T C
authors.initials: TC
authors.lastname: Boone
authors.forename: L M
authors.initials: LM
authors.lastname: Souza
authors.forename: C D
authors.initials: CD
authors.lastname: Lothrop
mesh_terms: D000818:Animals; D001772:Blood Cell Count / Q000662:veterinary; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation / Q000662:veterinary; D002478:Cells, Cultured; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000276:immunology / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000276:immunology; D007958:Leukocyte Count / Q000662:veterinary; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D009503:Neutropenia / Q000628:therapy / Q000662:veterinary*; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology; D009195:Peroxidase / Q000097:blood; D010587:Phagocytosis; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D009195:Peroxidase